Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Zacopride. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 5/20 | 0.98 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 2/20 | 0.98 |
| ▸ | HTR3B known ✓ | O95264 | 2/20 | 0.98 |
| ▸ | HTR3D known ✓ | Q70Z44 | 2/20 | 0.98 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 2/20 | 0.98 |
| ▸ | HTR5A known ✓ | P47898 | 1/20 | 0.98 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.61 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.61 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.61 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.61 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.61 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.98 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zacopride SCHEMBL7281576 | 1.00 | MAPK1 (0.98) | MAPK1HTR3AHTR3EHTR3BHTR3D | |
| Zacopride SCHEMBL7280998 | 1.00 | MAPK1 (0.98) | MAPK1HTR3AHTR3EHTR3BHTR3D | |
| Zacopride SCHEMBL667580 | 1.00 | MAPK1 (0.98) | MAPK1HTR3AHTR3EHTR3BHTR3D | |
| Zacopride SCHEMBL9598323 | 0.99 | MAPK1 (1.00) | MAPK1HTR3AHTR3EHTR3BHTR3D | |
| Zacopride SCHEMBL29389976 | 0.99 | MAPK1 (1.00) | MAPK1HTR3AHTR3EHTR3BHTR3D | |
| (R)Zacopride SCHEMBL5387843 | 0.99 | HTR3A (1.00) | MAPK1HTR3AHTR3EHTR3BHTR3D | |
| Zacopride SCHEMBL16003 | 0.99 | HTR3A (1.00) | MAPK1HTR3AHTR3EHTR3BHTR3D | |
| Zacopride SCHEMBL5373467 | 0.99 | HTR3A (1.00) | MAPK1HTR3AHTR3EHTR3BHTR3D | |
| Zacopride SCHEMBL29567897 | 0.99 | HTR3A (1.00) | MAPK1HTR3AHTR3EHTR3BHTR3D | |
| Zacopride SCHEMBL7200880 | 0.93 | HTR3A (0.88) | MAPK1HTR3AHTR3EHTR3BHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5206246-A | Anxiolytic agents | A. H. ROBINS COMPANY, INCORPORATED (US) | 1993-04-27 | — | — | US | disclosed |
| US-5017580-A | Memory enhancing-R-N-(1-azabicyclo[2.2.2.]oct-3-yl)benzamides and thiobenzamides | A.H. ROBINS COMPANY, INCORPORATED A VA CORPORATION | 1991-05-21 | — | — | US | disclosed |
| EP-0353371-A1 | Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1990-02-07 | — | — | EP | disclosed |
| EP-0311724-A1 | Anxiolytic-R-N-(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides | SYNTHELABO (FR) | 1989-04-19 | — | — | EP | disclosed |